Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (11-20 of 353) with videos related to

Pageof 36
Sort By:
Journal of the American College of Cardiology|March 25, 2026
Extending the Reach of GLP-1 Receptor Agonists for Cardiovascular Risk ReductionA Michael Lincoff
Reviews in Cardiovascular Medicine|November 20, 2002
Targeting the use of platelet IIb/IIIa inhibitors: treatment of acute myocardial infarctionA Michael Lincoff
JAMA|February 26, 2004
Coupling drug and catheter therapy for myocardial infarctionA Michael Lincoff
Cleveland Clinic Journal of Medicine|September 13, 2016
Dual antiplatelet therapy for acute coronary syndromes: How long to continue?Meghana Halkar, A Michael Lincoff
Evidence-Based Medicine|January 14, 2011
Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fondaparinuxAmar Krishnaswamy, A Michael Lincoff
Nature Reviews. Cardiology|September 14, 2011
Managing adverse effects and drug-drug interactions of antiplatelet agentsArun Kalyanasundaram, A Michael Lincoff,
Seminars in Thrombosis and Hemostasis|July 30, 2004
Bivalirudin in PCI: an overview of the REPLACE-2 trialAnjli Maroo, A Michael Lincoff
Circulation|June 25, 2014
Cardiovascular safety evaluation in the development of new drugs for diabetes mellitusVenu Menon, A Michael Lincoff
Cleveland Clinic Journal of Medicine|July 9, 2020
Stable coronary artery disease: Intervene or not?Vinayak Nagaraja, A Michael Lincoff
Cleveland Clinic Journal of Medicine|August 10, 2016
Should patients with stable ischemic heart disease undergo revascularization?Michael Chenier, A Michael Lincoff
Pageof 36

Showing results (11-20 of 353) with videos related to

Sort By:
Pageof 36
Journal of the American College of Cardiology|March 25, 2026
Extending the Reach of GLP-1 Receptor Agonists for Cardiovascular Risk ReductionA Michael Lincoff
Reviews in Cardiovascular Medicine|November 20, 2002
Targeting the use of platelet IIb/IIIa inhibitors: treatment of acute myocardial infarctionA Michael Lincoff
JAMA|February 26, 2004
Coupling drug and catheter therapy for myocardial infarctionA Michael Lincoff
Cleveland Clinic Journal of Medicine|September 13, 2016
Dual antiplatelet therapy for acute coronary syndromes: How long to continue?Meghana Halkar, A Michael Lincoff
Evidence-Based Medicine|January 14, 2011
Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fondaparinuxAmar Krishnaswamy, A Michael Lincoff
Nature Reviews. Cardiology|September 14, 2011
Managing adverse effects and drug-drug interactions of antiplatelet agentsArun Kalyanasundaram, A Michael Lincoff,
Seminars in Thrombosis and Hemostasis|July 30, 2004
Bivalirudin in PCI: an overview of the REPLACE-2 trialAnjli Maroo, A Michael Lincoff
Circulation|June 25, 2014
Cardiovascular safety evaluation in the development of new drugs for diabetes mellitusVenu Menon, A Michael Lincoff
Cleveland Clinic Journal of Medicine|July 9, 2020
Stable coronary artery disease: Intervene or not?Vinayak Nagaraja, A Michael Lincoff
Cleveland Clinic Journal of Medicine|August 10, 2016
Should patients with stable ischemic heart disease undergo revascularization?Michael Chenier, A Michael Lincoff
Pageof 36